Other languages LianBio

Equities

LIANY

US53000N1081

Market Closed - OTC Markets Other stock markets 03:55:19 2024-05-07 pm EDT			5-day change	1st Jan Change
0.3151 ^USD	+0.08%		+1.71%	-92.95%

May. 07	Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	MT
Mar. 18	LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	May. 07
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	Feb. 13
LianBio Announces Completion of Strategic Review	Feb. 13
Nanobiotix : transfert de droits sur NBTXR3 en Asie	Dec. 27
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Dec. 26
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	Dec. 26
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	Dec. 26
LianBio Finance Chief Resigns, Names Interim CFO	Dec. 20
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	Dec. 20
LianBio CEO Yizhe Wang Resigns; Board Member Adam Stone Named in Interim	Dec. 19
Lianbio Announces Resignation of Yizhe Wang as Member of the Board of Directors	Dec. 19
Lianbio Announces Chief Executive Officer Changes	Dec. 19
LianBio to Communicate an Update on the Ongoing Strategic Review in the First Quarter of 2024	Dec. 18
LianBio Rejects Concentra Biosciences' Unsolicited Acquisition Proposal	Dec. 07
Concentra Biosciences, LLC cancelled the acquisition of LianBio from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.	Dec. 05
LianBio Receives Unsolicited Proposal From Concentra Biosciences to be Acquired for $4.30 Per Share Plus Contingent Value Right	Dec. 01
LianBio Q3 Loss Widens	Nov. 13
LianBio Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	23-10-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages LianBio

Equities

LIANY

US53000N1081

Other languages

Filters